NEOPRONTOSIL (ORAL) IN THE TREATMENT OF CHRONIC ULCERATIVE COLITIS
Authors: Alex E. Brown, Wallace E. Herrell, J. Arnold Bargen
Journal: Annals of Internal Medicine (1939)

Article1 October 1939NEOPRONTOSIL (ORAL) IN THE TREATMENT OF CHRONIC ULCERATIVE COLITISALEX E. BROWN, M.D., F.A.C.P., WALLACE E. HERRELL, M.D., J. ARNOLD BARGEN, M.D., F.A.C.P.ALEX E. BROWN, M.D., F.A.C.P.Search for more papers by this author, WALLACE E. HERRELL, M.D.Search for more papers by this author, J. ARNOLD BARGEN, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-13-4-700 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptWith the advent of the various sulfamido compounds into the field of medical therapeutics it seemed reasonable, as we have stated in a previous article to investigate the effect of these preparations on patients who have chronic ulcerative colitis.In using the term "chronic ulcerative colitis," we are referring only to the thrombo-ulcerative form of the disease in which destructive and hyperplastic changes occur in the bowel. We felt that such a trial of therapy was justified because it seemed likely that the organism responsible for the disease might be susceptible to the effect of these sulfamido compounds. In a...References1. BANNICKBROWNFOSTER EGAEFP: Therapeutic effectiveness and toxicity of sulfanilamide and several related compounds: further clinical observations, Jr. Am. Med. Assoc., 1938, cxi, 770-777. CrossrefGoogle Scholar2. BARGEN JA: The management of colitis, 1935, National Medical Book Company, Inc., New York. Google Scholar3. BROWNHERRELLBARGEN AEWEJA: Neoprontosil (oral) in the treatment of chronic ulcerative colitis, Proc. Staff Meet. Mayo Clin., 1938, xiii, 561-565. Google Scholar4. BRUNSTINGGOECKERMANO'LEARY LAWHPA: Pyoderma (echthyma) gangrenosum; clinical and experimental observations in five cases occurring in adults, Arch. Dermat. and Syph., 1930, xxii, 655-680. CrossrefGoogle Scholar5. HERRELLBROWN WEAE: Clinical use of neoprontosil (oral), Proc. Staff Meet. Mayo Clin., 1938, xiii, 555-560. Google Scholar6. KINGHENSCHELGREEN JTAFBS: Influence of prontosil-soluble on beta hemolytic streptococci growing in tissue culture media, Proc. Soc. Exper. Biol. and Med., 1938, xxxviii, 810-812. CrossrefGoogle Scholar7. MARSHALL EK: Personal communication to the authors. Google Scholar8. RAIZISSSEVERACMOETSCHCLEMENCE GWMJCLW: The chemotherapy of sulfanilamide, prontosil soluble, di-sulfanilamide and proseptasine, Jr. Chemotherapy, 1938, xiv, 91-105. Google Scholar9. ROSENTHALBAUERBRANHAM SMHSE: Studies in chemotherapy. IV. Comparative studies of sulphonamide compounds in experimental pneumococcus, streptococcus, and meningococcus infections, Pub. Health Rep., 1937, lii, 662-671. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Rochester, Minnesota*Read at the New Orleans meeting of the American College of Physicians March 27, 1939. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byProblems in ulcerative colitis 1 October 1939Volume 13, Issue 4Page: 700-714KeywordsInflammatory bowel diseaseUlcerative colitis ePublished: 1 December 2008 Issue Published: 1 October 1939 PDF downloadLoading ...